Class IITerminated

Cefdinir for Oral Suspension USP recall

FDA recall D-0518-2024 · initiated May 8, 2024

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Defective container: lack of seal integrity.

Details

Product: Cefdinir for Oral Suspension USP, 250 mg/5 mL, packaged in a 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, Manufactured by: Lupin Limited, Mandideep, 462 046 India, NDC 68180-723-04
Recalling company: Lupin Pharms
Classification: Class II
Status: Terminated
Type: Voluntary: Firm initiated
Distribution: USA Nationwide
Initiated: May 8, 2024
FDA report date: Jun 5, 2024

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0518-2024 ↗

← All drug recalls